What does PERJETA treat?
PERJETA® (pertuzumab) is a prescription medicine approved for use in combination with Herceptin® (trastuzumab) and chemotherapy for:
Important Safety Information
Side effects may vary based on chemotherapy regimen.
You are encouraged to report side effects to Genentech and the FDA. You may report side effects to the FDA at 1-800-FDA-1088 or http://www.fda.gov/medwatch. You may also report side effects to Genentech at 1-888-835-2555.
Talk to a healthcare professional for more information about the benefits and risks of PERJETA.
Please see full Prescribing Information for additional Important Safety Information, including most serious side effects.
If you cannot afford your medication, visit genentech-access.com/patient for financial assistance information.
What does PHESGO treat?
PHESGO® (pertuzumab, trastuzumab, and hyaluronidase-zzxf) is a prescription medicine approved for use in combination with chemotherapy for:
Important Safety Information
What are the most common side effects?
The most common side effects of PHESGO when given with chemotherapy as part of an early breast cancer regimen are:
You are encouraged to report side effects to Genentech and the FDA. You may report side effects to the FDA at 1-800-FDA-1088 or http://www.fda.gov/medwatch. You may also report side effects to Genentech at 1-888-835-2555.
Talk to a healthcare professional for more information about the benefits and risks of PHESGO.
Please see full Prescribing Information for additional Important Safety Information, including most serious side effects.
If you cannot afford your medication, visit genentech-access.com/patient for financial assistance information.
Who is KADCYLA for?
Early Breast Cancer
KADCYLA is a prescription medicine used as an adjuvant (after surgery) treatment for HER2-positive early breast cancer when the patient has taken neoadjuvant (before surgery) treatment including taxane and trastuzumab (Herceptin®) and there is cancer remaining in the tissue removed during surgery. Patients are selected for therapy based on an FDA-approved test for KADCYLA.
Important Safety Information
What is the most Important Safety Information I should know about KADCYLA?
Liver problems
Heart problems
Pregnancy
Contact your doctor right away if you experience symptoms associated with these side effects.
What are the additional possible serious side effects of KADCYLA?
Lung problems
Infusion-related reactions
Serious bleeding
Low platelet count
Nerve damage
Skin reactions around the infusion site
What are the most common side effects of KADCYLA?
The most common side effects in people taking KADCYLA for early breast cancer are:
You are encouraged to report side effects to Genentech and the FDA. You may contact Genentech by calling 1-888-835-2555. You may contact the FDA by visiting www.fda.gov/medwatch or calling 1-800-FDA-1088.
Talk to a healthcare professional for more information about the benefits and risks of KADCYLA.
Please see full Prescribing Information for Important Safety Information, including most serious side effects.
If you cannot afford your medication, visit genentech-access.com/patient for financial assistance information.
What does PERJETA treat?
PERJETA® (pertuzumab) is a prescription medicine approved for use in combination with Herceptin® (trastuzumab) and chemotherapy for:
Important Safety Information
Side effects may vary based on chemotherapy regimen.
You are encouraged to report side effects to Genentech and the FDA. You may report side effects to the FDA at 1-800-FDA-1088 or http://www.fda.gov/medwatch. You may also report side effects to Genentech at 1-888-835-2555.
Talk to a healthcare professional for more information about the benefits and risks of PERJETA.
Please see full Prescribing Information for additional Important Safety Information, including most serious side effects.
If you cannot afford your medication, visit genentech-access.com/patient for financial assistance information.
The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.